摘要
目的探讨伊立替康联合顺铂新辅助化疗对局部晚期宫颈癌患者血清叶酸、鳞癌相关抗原(SCC-Ag)、糖类抗原125(CA125)水平的影响。方法选取2016年1月~2019年1月鄂钢医院收治的110例局部晚期宫颈癌患者作为研究对象。按照治疗方法分为对照组(55例)与观察组(55例)。对照组采用子宫全切手术前予以同步放化疗治疗方法,观察组采用子宫全切手术前予以伊立替康联合顺铂新辅助化疗治疗方法。比较两组的治疗总有效率、不良反应总发生率及治疗前后血清叶酸、SCC-Ag、CA125水平。结果观察组的治疗总有效率高于对照组,差异有统计学意义(P<0.05);治疗后,观察组血清叶酸水平高于治疗前,观察组血清叶酸水平高于对照组,差异有统计学意义(P<0.05);治疗后,观察组的SCC-Ag、CA125水平低于治疗前,观察组的SCC-Ag、CA125水平低于对照组,差异有统计学意义(P<0.05);两组的药物不良反应总发生率比较,差异无统计学意义(P>0.05)。结论伊立替康联合顺铂新辅助化疗治疗局部晚期宫颈癌患者疗效优于同步放化疗治疗,明显降低SCC-Ag、CA125水平和提高血清叶酸水平,且不会增加药物不良反应发生率。
Objective To investigate the effect of Irinotecan combined with Cisplatin neoadjuvant chemotherapy on serum levels of folic acid,squamous cell carcinoma associated antigen(SCC-AG)and carbohydrate antigen 125(CA125)in patients with locally advanced cervical cancer.Methods A total of 110 patients with locally advanced cervical cancer who were admitted to Egang Hospital from January 2016 to January 2019 were selected as the research subjects.According to the treatment method,they were divided into control group(55 cases)and observation group(55 cases).The control group was treated with concurrent chemoradiotherapy before total uterine resection,and the observation group was treated with Irinotecan combined with Cisplatin neoadjuvant chemotherapy before total uterine resection.The total effective rate of treatment,the total incidence of adverse reactions and serum folic acid,SCC-Ag and CA125 levels before and after treatment were compared between the two groups.Results The total effective rate in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the serum folate level in the observation group was higher than that before treatment,and the serum folate level in the observation group was higher than that in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of SCC-Ag and CA125 in the observation group were lower than those before treatment,and the levels of SCC-Ag and CA125 in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse drug reactions between the two groups(P>0.05).Conclusion The treatment of Irinotecan combined with Cisplatin neoadjuvant chemotherapy is more effective than concurrent chemoradiotherapy in the treatment of with patients locally advanced cervical cancer.It can significantly reduce the levels of SCC-Ag and CA125,increase serum levels of folic acid,without increasing the incidence of adverse drug reactions.
作者
高贤琼
GAO Xian-qiong(Department of Inpatient in Western Pharmacy with Drug and Equipment,Egang Hospital,Hubei Province,Ezhou436000,China)
出处
《中国当代医药》
CAS
2021年第6期51-54,共4页
China Modern Medicine
关键词
伊立替康
顺铂
新辅助化疗
宫颈癌
叶酸
鳞癌相关抗原
糖类抗原125
Irinotecan
Cisplatin
Neoadjuvant chemotherapy
Cervical cancer
Folic acid
Squamous cell carcinoma associated antigen
Carbohydrate antigen 125
